Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Treatments

Topic: Drug trials: efficacy and safety

Plain-language summary

SCarlet RoAD (NCT01224106; WN25203), a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-year study of gantenerumab in prodromal AD, was the first global registration-enabling study using biomarker screening for entry and a single clinical endpoint for outcome. Dosing was terminated in December 2014 following a pre-planned futility analysis; patients continue to be followed. Efficacy data for 2-year completers (n=312) and all ITT safety data (n=797) are presented. Patients were 50–85 years old with MMSE scores ≥24, CDR-Global scores of 0.5 (memory box scores of 0.5 or 1.0) and evidence of amyloid pathology (CSF Aβ42 <600 ng/mL, Innotest), with cognition and functional performance largely preserved to exclude a diagnosis of AD dementia. Patients were randomized to monthly subcutaneous injections of placebo, or 105 mg or 225 mg gantenerumab, depending on their APOEe4 allele status (no APOEe4 homozygotes received 225 mg). Primary endpoint at 2 years was CDR-Sum of Boxes (SB) total score; secondary endpoints included ADAS-Cog 13, FAQ and MMSE. Biomarker results are presented separately. No differences in CDR-SB scores between placebo and gantenerumab treatment groups over 2 years were found, with similar findings for ADAS-Cog 13, FAQ and MMSE. PK/PD modeling showed an exposure-dependent trend for clinical benefit in patients that were predicted to have a faster rate of progression over the duration of the trial. Serious adverse events were reported in 19.5%, 17.3% and 16.9% of patients in the placebo, 105 mg and 225 mg gantenerumab arms, respectively. ARIA were dose- and APOEε4allele-dependent. Overall incidence of ARIA for placebo, 105 mg and 225 mg gantenerumab groups was 0.8%, 6.6% and 12.3% for ARIA-E, and 10.9%, 19.2% and 13.1% for ARIA-H, respectively. Additional exploratory analyses will be presented. Gantenerumab, a human anti-Aβ antibody with high affinity to aggregated Aβ, was well tolerated by patients with prodromal AD over the dose range tested in this dataset, one of the larger controlled datasets in prodromal AD patients available to date. No significant differences in primary efficacy endpoints between treatment arms were observed. Exploratory analyses are ongoing and will help guide further development of gantenerumab.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Lasser, R. A., Ostrowitzki, S., Scheltens, P., Boada, M., Dubois, B., Dorflinger, E. E., et al. (2015). DT‐01‐03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road—a global, multicenter trial. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2015.08.153

Vancouver

Lasser RA, Ostrowitzki S, Scheltens P, Boada M, Dubois B, Dorflinger EE, et al. DT‐01‐03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road—a global, multicenter trial. Alzheimer s & Dementia. 2015. doi:10.1016/j.jalz.2015.08.153.

BibTeX

@article{lasser2015-f0473682,
  author  = {Lasser, Robert A. and Ostrowitzki, Susanne and Scheltens, Philip and Boada, Merçé and Dubois, Bruno and Dorflinger, Ernest E. and Balas, Bogdan and Nikolcheva, Tania and others},
  title   = {{DT‐01‐03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road—a global, multicenter trial}},
  journal = {Alzheimer s \& Dementia},
  year    = {2015},
  doi     = {10.1016/j.jalz.2015.08.153},
  url     = {https://doi.org/10.1016/j.jalz.2015.08.153}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 55/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 0 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 1 of 2; Free to read 0 of 2. 32 of the 58 points it could be judged on, which is 55 of 100. Total 55 of 100.32 of the 58 points we could judge = 55 of 100

Published in a peer-reviewed journal. Scored zero for study design because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 32 of the 58 points we could judge it on, which is 55 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 0 / 12 Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2015 — within 20 year(s) of the newest study here
Sample size 2 / 4 312 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 0 / 2 Behind a paywall — scores zero
Points 32 / 58 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 32 of the 58 points we could judge it on is 55 out of 100.
Total 55 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also tagged “monoclonal”

332 studies in the library carry the topic tag “monoclonal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →